Trial Profile

Alendronate in an Weekly Effervescent Tablet Formulation for Preservation of Bone Mass After Denosumab Discontinuation in Postmenopausal Women with Low Bone Mass. an Observational Study (Binosto After Denosumab - the BAD Study)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alendronic acid (Primary) ; Calcium carbonate; Colecalciferol; Denosumab
Indications Postmenopausal osteoporosis
Focus Therapeutic Use
Acronyms BAD

02 Dec 2024 Status changed from active, no longer recruiting to completed.
28 Sep 2023 Planned End Date changed from 1 Oct 2024 to 1 Nov 2024.
28 Sep 2023 Planned primary completion date changed from 1 Oct 2023 to 25 Sep 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com